Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
Single doses were administered intravenously and changes from baseline values of left ventricular EF were measured for each patient.
- Single doses were administered intravenously and changes from baseline values of left ventricular EF were measured for each patient.
- We are also excited to now be recruiting for the first clinical trial with our IL15-CTLA4 antibody fusion, JK08, and we expect to share initial data in 2023.
- JK08 was designed based on clinical studies from both individual molecules, which together portend synergistic effects in an antibody fusion construct.
- A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 13) in Patients With Systolic Dysfunction and Heart Failure.